Form 4: RELMADA Officer Granted 828K Stock Appreciation Rights

RELMADA Therapeutics officer Chuck Ence was granted 828,000 stock appreciation rights with a $4.06 exercise price, vesting quarterly from March 2026.

Summary

• Chuck Ence, an officer (Chief Accounting Officer and Controller) of RELMADA Therapeutics, Inc. (RLMD), was granted 828,000 Stock Appreciation Rights (SARs).
• The SARs have an exercise price of $4.06 per right.
• The grant date for these SARs was December 12, 2025.
• These SARs will vest in 16 equal quarterly installments, beginning on March 12, 2026.
• The expiration date for these SARs is December 12, 2035.
• Following this transaction, Chuck Ence beneficially owns 828,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of significant equity incentives to a key officer is generally a positive signal for executive retention and alignment with shareholder interests, though it's a standard compensation event rather than a direct operational or financial performance indicator.

Positives

• The grant of 828,000 Stock Appreciation Rights to a key officer aligns management's incentives with shareholder value creation.
• The vesting schedule over four years (16 quarterly installments) promotes long-term retention and performance of the executive.

Negatives

• There is no immediate cash value for the officer until the SARs vest and the company's stock price exceeds the exercise price of $4.06.
• The value of the SARs is entirely dependent on future stock price appreciation, introducing market risk for the compensation.

Risks

• The value of the Stock Appreciation Rights is contingent on the company's stock price exceeding the $4.06 exercise price, exposing the officer to market risk.
• Future stock price performance may not be sufficient to make the SARs valuable, potentially impacting executive motivation if the stock underperforms.

Future Outlook

The grant of long-term equity incentives like Stock Appreciation Rights suggests a strategic focus on retaining key executives and aligning their performance with the company's long-term stock price appreciation. The vesting schedule extends over several years, indicating a commitment to future performance.

Industry Context

Equity compensation, such as Stock Appreciation Rights, is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key talent, particularly in companies like RELMADA Therapeutics that may be in development stages and rely on future growth. This aligns executive interests with long-term shareholder value creation, a standard approach in growth-oriented sectors.

Comparison to Industry Standards

• The use of Stock Appreciation Rights (SARs) as executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, comparable to grants seen at companies like Moderna or BioNTech for their executives, aiming to incentivize long-term stock performance without immediate share dilution.
• A vesting schedule of 16 equal quarterly installments over four years is typical for long-term incentive plans, similar to those observed at peer companies to ensure executive retention and sustained performance.
• The exercise price of $4.06, being the market price at the time of grant (implied, as SARs are typically granted at fair market value), is consistent with industry best practices for equity awards.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value creation, as the SARs gain value only if the stock price appreciates.
• Employees: May signal a commitment to competitive executive compensation, potentially influencing overall employee morale and retention strategies.

Next Steps

• Monitoring the vesting schedule of the Stock Appreciation Rights commencing March 12, 2026.
• Observing future Form 4 filings for any exercise or disposition of these SARs or other securities by Chuck Ence.

Key Dates

Recommendation

This Form 4 reports a standard grant of Stock Appreciation Rights to a company officer as part of their compensation package. While it aligns executive incentives with long-term shareholder value, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a routine compensation disclosure.

Keywords

RELMADA Therapeutics, RLMD, Stock Appreciation Rights, SARs, Insider Grant, Executive Compensation, Form 4, Derivative Securities, Equity Compensation, Officer Grant